A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.
Cortés J. et al, (2025), Clin Cancer Res, 31, 4953 - 4963
Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.
Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48
Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2025)
Figure 1 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2025)
Figure 2 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2025)
Figure 3 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2025)
Figure 4 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2025)
Figure 5 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2025)
Figure 6 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2025)
Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis.
Pinho MP. et al, (2025), Cell Rep Med, 6
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2025), Nat Commun, 16
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.
Di Giovannantonio M. et al, (2025), Cell Genom, 5
The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.
Greene J. et al, (2025), Cancer Control, 32
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
Javed SR. et al, (2024), Br J Cancer, 131, 1724 - 1736
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43
New role of fat-free mass in cancer risk linked with genetic predisposition.
Harris BHL. et al, (2024), Sci Rep, 14
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR. et al, (2024), Br J Cancer, 130, 467 - 475